Innocan Pharma hires Lytham Partners to lead investor relations and shareholder communications program

Herzliya, Israel and Calgary, Alberta – (Newsfile Corp. – May 10, 2021) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the “Company” or “Innocan”) announced today hui he retained the services of Lytham Partners, LLC (“Lytham Partners”) to lead an investor relations and shareholder communications program.

For over 20 years, Lytham Partners has been one of the industry’s leading investor relations firms, having created one of the largest and most diverse institutional investor networks, while creating a framework of best practices. in all aspects of corporate and shareholder communication. Lytham Partners works with many NASDAQ-listed companies to properly and effectively communicate their value to the institutional investment community.

Iris Bincovich, Managing Director of Innocan Pharma, said: “We have made significant progress since becoming a publicly traded company in September 2019. Our proprietary and differentiated research projects continue to deliver highly innovative treatments and provide a solid return on investment. integral geography as it relates to our science endeavors, and we believe now is an appropriate time to broaden our awareness within the U.S. investment community. We look forward to working with the team at Lytham Partners, who have a solid understanding of the pharmaceutical and cannabis space, to further assist us in these efforts. “

Ben Shamsian, Vice President of Lytham Partners, said: “Given Innocan Pharma’s strong scientific advancement profile, we believe the US investment community will be interested in learning more about their unique value proposition and future opportunities to create shareholder value. present the company to our investor platform, while installing best practices within their communication program at all levels to keep shareholders informed of current developments in the company. “

As part of this commitment, Lytham Partners will receive compensation of $ 6,500 per month.

About Innocan

The Company, through its 100% Israeli subsidiary, Innocan Pharma Ltd. (“Innocan Israel”), is a pharmaceutical technology company focused on the development of multiple drug delivery platforms combining cannabidiol (“CBD“). Innocan Israel and Ramot of Tel Aviv University are collaborating on a revolutionary new exosome-based technology that targets both central nervous system (CNS) indications and the Covid-19 coronavirus using CBD. Exosomes loaded with CBD have the potential to help. This product, which should be administered by inhalation, will be tested against various lung infections.

Innocan Israel has signed an exclusive global licensing agreement with Yissum, the commercial arm of the Hebrew University of Jerusalem to develop a unique controlled-release liposome-based CBD drug delivery platform for injection. Innocan Israel plans, in collaboration with Professor Berenholtz, head of the Hebrew University Membrane and Liposome Research Laboratory, to test the liposome platform on several potential indications. Innocan Israel is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of pharmaceutical products integrated with CBD, including, but not limited to, topical treatments for the relief of pain. symptoms of psoriasis as well as muscle treatment. pain and rheumatic pain. Innocan’s founders and executives have a successful track record in the pharmaceutical and technology industries in Israel and around the world.

For more information, please contact:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+ 972-54-3012842
[email protected]

Lytham Partners, LLC
Ben shamsian
New York | Phoenix
Telephone: 646-829-9701
shamsia[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATORY SERVICE PROVIDERS HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information and statements set forth in this press release, including, without limitation, information regarding markets, required regulatory approvals and expected timing of market entry, are forward-looking information and forward-looking statements. within the meaning of applicable securities laws (collectively “forward-looking information”). By their nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this press release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions regarding the expected benefits of trading on the OTCQB Venture market and eligibility for DTC, including increasing liquidity and expanding our shareholder base; and establishing a strong presence for our company in the U.S. financial markets, product benefits, meeting regulatory requirements in various jurisdictions and l ‘satisfactory completion of required production and distribution agreements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from anticipated results or expectations expressed in this press release. Principal risks and uncertainties include, but are not limited to: general global and local (national) economic, business and business conditions; government and regulatory requirements and actions of government authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors and that our common stock liquidity and our shareholder base will not increase. There are also risks inherent in the nature of product distribution, including import / export issues and failure to obtain required (or timely) regulatory and other approvals and availability on the market. each market of product inputs and finished products. some products. The expected timeframe for market entry may change for a number of reasons, including the inability to meet the necessary regulatory requirements or the need for more time to enter into and / or meet manufacturing and manufacturing agreements. distribution. In view of the foregoing, readers should not place undue reliance on the forward-looking information contained in this press release regarding the timing of the commencement of distribution of the products. A full discussion of other risks that impact Innocan can also be found in Innocan’s public reports and documents, available under Innocan’s profile at www.sedar.com.

Readers are cautioned not to place undue reliance on forward-looking information, as actual results may differ materially from forward-looking information. Innocan does not undertake to update, correct or revise forward-looking information as a result of any new information, future events or otherwise, except as required by applicable law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/83474


Source link

About Margie Peters

Check Also

Sai Life Sciences Pharmaceutical API Manufacturing Site Receives Inspection Certificate from PMDA, Japan

Make the announcement, Krishna Kanumuri, CEO and Managing Director, said: “We are delighted to receive …

Leave a Reply

Your email address will not be published. Required fields are marked *